Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATAC Endometrial Sub-protocol
NCT00814125Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 1997
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial of anastrozole in breast cancer (3 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of abnormal endometrial histological findings, Withdrawal and 1 more. Started Jun 1997; status: completed.
02
Drugs
anastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00814125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00814125.